These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9645897)

  • 21. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction.
    Rochon PA; Tu JV; Anderson GM; Gurwitz JH; Clark JP; Lau P; Szalai JP; Sykora K; Naylor CD
    Lancet; 2000 Aug; 356(9230):639-44. PubMed ID: 10968437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of All-Cause Mortality in Diabetic Patients Taking β-Blockers.
    Tsujimoto T; Kajio H; Shapiro MF; Sugiyama T
    Mayo Clin Proc; 2018 Apr; 93(4):409-418. PubMed ID: 29545006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of beta-blockers on the mortality of Japanese patients with myocardial infarction.
    Yamada K; Tsuji H; Tokunaga S; Kurimoto K; Maeba H; Matsuhisa S; Inami N; Iwasaka T
    Int J Cardiol; 2006 Apr; 108(3):309-13. PubMed ID: 15970341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients.
    Braun S; Boyko V; Behar S; Reicher-Reiss H; Shotan A; Schlesinger Z; Rosenfeld T; Palant A; Friedensohn A; Laniado S; Goldbourt U
    J Am Coll Cardiol; 1996 Jul; 28(1):7-11. PubMed ID: 8752787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery.
    Chan AY; McAlister FA; Norris CM; Johnstone D; Bakal JA; Ross DB;
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):182-7, 187.e1. PubMed ID: 20427056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
    Park KL; Goldberg RJ; Anderson FA; López-Sendón J; Montalescot G; Brieger D; Eagle KA; Wyman A; Gore JM;
    Am J Med; 2014 Jun; 127(6):503-11. PubMed ID: 24561113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control?
    Poldermans D; Bax JJ; Schouten O; Neskovic AN; Paelinck B; Rocci G; van Dortmont L; Durazzo AE; van de Ven LL; van Sambeek MR; Kertai MD; Boersma E;
    J Am Coll Cardiol; 2006 Sep; 48(5):964-9. PubMed ID: 16949487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group.
    Harpaz D; Gottlieb S; Graff E; Boyko V; Kishon Y; Behar S
    Am J Med; 1998 Dec; 105(6):494-9. PubMed ID: 9870835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness of beta-blockers after myocardial infarction in patients with type 2 diabetes.
    McDonald CG; Majumdar SR; Mahon JL; Johnson JA
    Diabetes Care; 2005 Sep; 28(9):2113-7. PubMed ID: 16123475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery.
    Kertai MD; Boersma E; Westerhout CM; Klein J; Van Urk H; Bax JJ; Roelandt JR; Poldermans D
    Eur J Vasc Endovasc Surg; 2004 Oct; 28(4):343-52. PubMed ID: 15350554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional class in patients with heart failure is associated with the development of diabetes.
    Tenenbaum A; Motro M; Fisman EZ; Leor J; Freimark D; Boyko V; Mandelzweig L; Adler Y; Sherer Y; Behar S
    Am J Med; 2003 Mar; 114(4):271-5. PubMed ID: 12681453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?
    Kernis SJ; Harjai KJ; Stone GW; Grines LL; Boura JA; O'Neill WW; Grines CL
    J Am Coll Cardiol; 2004 May; 43(10):1773-9. PubMed ID: 15145098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of Vasodilating β-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study.
    Chung J; Han JK; Kim YJ; Kim CJ; Ahn Y; Chan Cho M; Chae SC; Chae IH; Chae JK; Seong IW; Yang HM; Park KW; Kang HJ; Koo BK; Jeong MH; Kim HS;
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
    Ozasa N; Morimoto T; Bao B; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Tazaki J; Natsuaki M; Kimura T;
    Int J Cardiol; 2013 Sep; 168(2):774-9. PubMed ID: 23127614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
    Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
    Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin and beta-blocker therapy and the initial presentation of coronary heart disease.
    Go AS; Iribarren C; Chandra M; Lathon PV; Fortmann SP; Quertermous T; Hlatky MA;
    Ann Intern Med; 2006 Feb; 144(4):229-38. PubMed ID: 16490908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction.
    Hioki H; Motoki H; Izawa A; Kashima Y; Miura T; Ebisawa S; Tomita T; Miyashita Y; Koyama J; Ikeda U
    Heart Vessels; 2016 May; 31(5):687-93. PubMed ID: 25863805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification.
    Providência R; Boveda S; Defaye P; Segal O; Algalarrondo V; Sadoul N; Lambiase P; Piot O; Klug D; Perier MC; Bouzeman A; Barra S; Bories MC; Gras D; Fauchier L; Bordachar P; Babuty D; Deharo JC; Leclercq C; Marijon E;
    Am J Cardiol; 2016 Oct; 118(8):1225-1232. PubMed ID: 27561197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.
    Bangalore S; Bhatt DL; Steg PG; Weber MA; Boden WE; Hamm CW; Montalescot G; Hsu A; Fox KA; Lincoff AM
    Circ Cardiovasc Qual Outcomes; 2014 Nov; 7(6):872-81. PubMed ID: 25271049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.